《柳叶刀-肿瘤》2025年修正；26日:200 - 13所示

The Lancet Oncology Pub Date : 2025-04-30 DOI:10.1016/s1470-2045(25)00210-4

{"title":"《柳叶刀-肿瘤》2025年修正；26日:200 - 13所示","authors":"","doi":"10.1016/s1470-2045(25)00210-4","DOIUrl":null,"url":null,"abstract":"Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2025; 26: 200–13—In figure 2 of this Article, the data for age, splenomegaly, and extranodal disease were incorrect and have been amended. These corrections have been made to the online version as of April 30, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"136 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2025; 26: 200–13\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(25)00210-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2025; 26: 200–13—In figure 2 of this Article, the data for age, splenomegaly, and extranodal disease were incorrect and have been amended. These corrections have been made to the online version as of April 30, 2025.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"136 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(25)00210-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00210-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Wang M, Jurczak W, trenny M，等。伊鲁替尼联合venetoclax治疗复发或难治性套细胞淋巴瘤（SYMPATICO）：一项多中心、随机、双盲、安慰剂对照的3期研究。柳叶刀肿瘤学杂志2025；26: 200 - 13在本文的图2中，年龄、脾肿大和结外疾病的数据不正确，已被修改。这些更正已于2025年4月30日对在线版本进行了修改。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Oncol 2025; 26: 200–13

Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2025; 26: 200–13—In figure 2 of this Article, the data for age, splenomegaly, and extranodal disease were incorrect and have been amended. These corrections have been made to the online version as of April 30, 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Lancet Oncology

自引率

0.00%

发文量